Xu Jingren briefs about the Jiangsu Pharmaceutical Co., Ltd.

            
                          Li Weimin (left) and his delegates on a visit to No.2 Workshop of Freeze Dry Powder Preparation

            
                                                                                       The Site of Signing Ceremony

            
                                                  Xu Jingren and Director Li Weimin sign the partnership agreement

Building industry-university-institute cooperation platforms can help the translation of innovation results into industrialized products. On October 25, Yangtze River Pharmaceutical Group and West China Hospital of Sichuan University held the signing ceremony of industry-university-institute cooperation framework in Taizhou. Li Weimin, Director of West China Hospital of Sichuan University, Cheng Jingqiu, Vice Director of West China Hospital, Xu Jingren, Chairman of Yangtze River Pharmaceutical Group, Mark Powel, Honorary Dean of Yangtze River Pharmaceutical Group New Medicine Research Institute, Xia Wenle, the Senior Advisor, etc. attended the ceremony. Lv Qiang, Vice General Manager and Chief Science Officer of Yangtze River Pharmaceutical Group, chaired the ceremony. Prior to the signing ceremony, Director Li and his delegation visited the Changzhou Zilong Pharmaceutical Co., Ltd. of Yangtze River Pharmaceutical Group, which was under construction. At the construction site, Director Li expressed his amazement at the Yangtze River Pharmaceutical Group's rapid growth. On the No.2 Workshop of Oral Solution in the headquarters, bottles of oral solution were accurately and rapidly packed into boxes by machine arms. Director Li was enthralled by the modern streamlined production workshop while asking the production procedures of medicine and operation of equipment. Knowing that the workshop applies EU GMP management ideas, uses predominantly import equipment, was highly automatic with its main product Lanqin oral solution appointed the chief medicine against children's hand, foot and mouth disease by the Ministry of Health, the delegation showed their admiration. During the ceremony, Xu Jingren told Li's delegation that the Company was constantly enhancing its innovation, introducing high-end personnel, and building state-class corporate technological center and other high end R&D platforms such as National Key Laboratory, using industry-institute-university cooperation and intensifying independent innovation and new medicine research and development. The company has developed an array of new medicines of good effectiveness and quality, such as Weisu granules, Dizocine injection, Suhuang Zhike capsules. Xu Jingren declared that the two parties would jointly build a transferring medical joint laboratory in Tianfu Life Science Park of Chengdu to seek innovative results on the new medicine, diagnosis and treatment. Director Li Weimin said that he and his delegation were deeply impressed with Chairman Xu Jingren's courage and vision, the down-to-earth ethos of Yangtze River Pharmaceutical Group, the beautiful environment, the stringent quality management, and the cultural profundity. As an outstanding representative of national medicine, Yangtze River Pharmaceutical Group blessed consumers with numerous products of good quality and effectiveness. With Yangtze River Pharmaceutical Group having competitive edges in industrial chain research and innovation and capital and West China Hospital holding abundant scientific innovation and clinical resource, the two parties' could, in the spirit of being complementary to each other, mutual benefit, mutual help and joint development, give full play to their own advantages, conduct track and research in state of art technology and apply for major research topics relying on the industry-university-institute cooperation platform. Meanwhile, the two parties could build personnel teams and conduct cooperation and exchange on personnel. Medicine research and development is the essence for the survival and development of pharmaceutical companies. Over the past few years, Yangtze River Pharmaceutical Group has been following the path of independent innovation and incrementally push forward the transformation of made in Yangtze River Pharmaceutical Group to create in Yangtze River Pharmaceutical Group. The establishment of industry-institute-research strategic partnership would continue to enhance the independent innovation capacity of Yangtze River Pharmaceutical Group and the education and research of West China Hospital, promote the integration of science, technology and economics, and support the win-win results and development of national pharmaceutical industry.